SERENITY At-Home phase III trial evaluating BXCL 501, sublingual film formulation of dexmedetomidine, met its endpoint as an acute treatment for bipolar/schizophrenia agitation – BioXcel Therapeutics
-BioXcel Therapeutics, Inc announced that the SERENITY At-Home Pivotal Phase III trial evaluating the safety of BXCL 501, the Company’s proprietary, sublingual film formulation of dexmedetomidine, as an… read more.
